A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
During the dose escalation phase of the study, cohorts of 3 to 6 subjects with metastatic or locally advanced solid tumors will receive KD033 at escalating dose levels. Upon completion of the dose escalation part of the study, at least 15 subjects will be enrolled in the expansion cohort to further ...
During the dose escalation phase of the study, cohorts of 3 to 6 subjects with metastatic or locally advanced solid tumors will receive KD033 at escalating dose levels. Upon completion of the dose escalation part of the study, at least 15 subjects will be enrolled in the expansion cohort to further confirm the recommended phase 2 dose.
Tracking Information
- NCT #
- NCT04242147
- Collaborators
- Not Provided
- Investigators
- Not Provided